コンテンツへスキップ
Merck
すべての画像(1)

主要文書

すべての文書を表示

安全性情報

A-008

Supelco

S(+)-Amphetamine (dextro-Amphetamine) solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

別名:

dextro-Amphetamine

ログイン組織・契約価格を表示する
すべての画像(1)

About This Item

実験式（ヒル表記法）:
C9H13N
CAS番号:
51-64-9
分子量:
135.21
MDL番号:
MFCD00133300
UNSPSCコード:
41116107
PubChem Substance ID:
329770571
NACRES:
NA.24

グレード

certified reference material

フォーム

liquid

特徴

SNAP-N-SPIKE®. SNAP-N-SHOOT®

包装

ampule of 1 mL

メーカー／製品名

Cerilliant®

drug control

Narcotic Licence Schedule A (Switzerland); psicótropo (Spain); Decreto Lei 15/93: Tabela IIB (Portugal)

濃度

1.0 mg/mL in methanol

テクニック

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

アプリケーション

forensics and toxicology

フォーマット

single component solution

保管温度

−20°C

SMILES記法

C[C@H](N)Cc1ccccc1

InChI

1S/C9H13N/c1-8(10)7-9-5-3-2-4-6-9/h2-6,8H,7,10H2,1H3/t8-/m0/s1

InChI Key

KWTSXDURSIMDCE-QMMMGPOBSA-N

遺伝子情報

human ... SLC18A2(6571)

詳細

Amphetamine is a stimulant of the phenethylamine class found in ADHD-treatment drugs such as Adderall®, Vyvanse®, and ProCentra®. Because of its stimulant effect, amphetamine is used recreationally as a performance-enhancer and illicit drug. This Certified Snap-N-Spike® Solution is suitable for use in urine drug testing, clinical toxicology, forensic analysis, and isomer identification by LC-MS/MS or GC/MS.

法的情報

Adderall is a registered trademark of Richwood Pharmaceutical Company, Inc.
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
ProCentra is a registered trademark of Outlook Pharmaceuticals, Inc.
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Vyvanse is a registered trademark of Shire, LLC

関連製品

製品番号
詳細
価格

A-016

(±)-Amphetamine-d11 solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

A-050

Amine Mixture-6 solution, 250 μg/mL each component in methanol, ampule of 1 mL, certified reference material, Cerilliant®

A-002

(±)-Amphetamine-d5 (deuterium label on ring) solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

A-005

(±)-Amphetamine-d5 (deuterium label on side chain) solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

A-007

(±)-Amphetamine solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

A-013

(±)-Amphetamine-d5 (deuterium label on side chain) solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

A-017

(±)-Amphetamine-d8 solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

A-018

(±)-Amphetamine-d8 solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

A-019

(±)-Amphetamine-d11 solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

A-044

(±)-Amphetamine-d6 solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

A-045

(±)-Amphetamine-d6 solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

A-049

R(-)-Amphetamine (levo-Amphetamine), 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

E-018

(±)-N-Ethylamphetamine solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

L-026

Lisdexamfetamine dimesylate solution, 1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®

L-028

Lisdexamfetamine-D4 dimesylate solution, 100 μg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®

P-050

PMA 塩酸塩 溶液, 1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®

A-212

(±)-Amphetamine-13C6 hydrochloride solution, 100 μg/mL in methanol ((as free base)), certified reference material, ampule of 1 mL, Cerilliant®

ピクトグラム

FlameSkull and crossbonesHealth hazard
GHS02,GHS06,GHS08

シグナルワード

Danger

危険有害性情報

H225,H301 + H311 + H331,H370

危険有害性の分類

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

ターゲットの組織

Eyes,Central nervous system

保管分類コード

3 - Flammable liquids

WGK

WGK 2

引火点(°F)

49.5 °F - closed cup

引火点(℃)

9.7 °C - closed cup

適用法令

試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。

消防法

第4類:引火性液体
アルコール類
危険等級II

労働安全衛生法名称等を表示すべき危険物及び有害物

名称等を表示すべき危険物及び有害物

労働安全衛生法名称等を通知すべき危険物及び有害物

名称等を通知すべき危険物及び有害物

Jan Code

A-008-CC:
A-008-1ML:

最新バージョンのいずれかを選択してください：

試験成績書（COA）

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 資料 section.

サポートが必要な場合は、お問い合わせください カスタマーサポート

以前この製品を購入いただいたことがある場合

文書ライブラリで、最近購入した製品の文書を検索できます。

文書ライブラリにアクセスする

J H Check et al.
Clinical and experimental obstetrics & gynecology, 40(2), 227-228 (2013-08-27)
To further investigate the efficacy of treatment of interstitial cystitis that had been refractory to standard treatment with sympathomimetic amines. Dextroamphetamine sulfate sustained release capsules up to 30 mg per day were prescribed in women with refractory painful bladder syndrome/interstitial
Sanders A McDougall et al.
Pharmacology, biochemistry, and behavior, 104, 154-162 (2013-01-31)
The early ontogeny of D-amphetamine-induced one-trial behavioral sensitization was characterized using male and female preweanling and preadolescent rats. In Experiment 1, rats were injected with saline or D-amphetamine (1, 4, or 8mg/kg) in activity chambers or the home cage on
J H Check et al.
Clinical and experimental obstetrics & gynecology, 40(2), 284-285 (2013-08-27)
Sympathetic nervous system hypofunction has been found to be associated with motility disorders of the bowel, including gastroparesis, pseudointestinal obstruction, and esophageal motility disorders. These disorders respond to sympathomimetic amine therapy. The purpose of this study was to see if
Greg W Mattingly et al.
BMC psychiatry, 13, 39-39 (2013-01-30)
Despite the overall high degree of response to pharmacotherapy, consensus is lacking on how to judge clinical response or define optimal treatment/remission when treating adults with attention-deficit/hyperactivity disorder (ADHD). This study examined clinical response and symptomatic remission in analyses of
Joel L Young
Postgraduate medicine, 125(1), 162-168 (2013-02-09)
Fatigue is commonly reported in the primary care setting; however, its cause is often unclear. This article presents 3 cases involving patients with chronic fatigue syndrome who responded poorly to treatment. After clinical evaluation, all patients were found to meet
関連する文献をすべて表示

資料

LC/MS Analysis of Amphetamine Enantiomers on Astec CHIROBIOTIC® V2 in Urine after Solid Phase Extraction (SPE) using Supel™-Select SCX

Shown here is the chiral separation of amphetamine enantiomers under MS-compatible conditions on Astec CHIROBIOTIC® V2 after extraction from urine using Supel™-Select SCX SPE 96-well plates. The highest grade mobile phase solvents and additives were used to supply low background interference and low particulate contaminants for robust, trouble-free operation. Cerilliant CRMs provided reliable identification and quantification.

プロトコル

Accurate Biological Testing for Amphetamine and Methamphetamine Abuse Using Chiral HPLC and MS Detection

Optimized sample prep and chiral chromatography methods for the LC/MS analysis of these drug enantiomers in urine

Biological Testing for Amphetamine and Methamphetamine Abuse

In this study, optimized methods are presented for sample preparation and chiral chromatography for the LC/MS analysis of amphetamine and methamphetamine enantiomers in urine.

ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.

製品に関するお問い合わせはこちら（テクニカルサービス）